Navigation Links
Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Date:2/25/2009

. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. It is being studied in multiple cancer indications, treatment combinations and by two routes of administration.

In addition to the Phase 2 clinical trial in metastatic CRPC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. Picoplatin is also being evaluated in an ongoing Phase 2 clinical trial in patients with metastatic colorectal cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's results of clinical trials to date, business objectives and strategic goals, drug development plans, the potential safety and efficacy of its products in development and commercialization strategy. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of clinical testing; the rece
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
4. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
8. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Switzerland (PRWEB) March 03, 2015 ... for drug discovery and life science research, today ... Biologics (TM) enterprise platform for use at Pfizer ... and Europe. Genedata is supporting Pfizer’s global deployment ... Technologies (GBT), Centers for Therapeutic Innovation (CTI), and ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "RNAi - Technologies, ... Because of its ability to silence any ... adopted as the research tool to discriminate gene function. ... can be designed to target every gene in the ...
(Date:3/3/2015)... 3, 2015 Elsevier,s DirectCourse ... implementing competency-based training to comply with new CMS requirements ... offering a new crosswalk tool to help ... training for direct service workers as a means to ... (CMS) regulations. CMS amended the regulations, effective ...
(Date:3/3/2015)... , March 3, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... sustainable chemicals, today announced it has initiated commissioning activities ... in Sarnia, Ontario , Canada.  ... approximately five months, with the facility being in commercial ... be completed in two months and it is carrying ...
Breaking Biology Technology:Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3
... /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS),a leading developer in ... Giese, President and CEO, will present at the,Rodman and Renshaw ... WHEN: Monday May 19th at 11:25 ... Beach Plaza Hotel, Monte Carlo, About Rodman and Renshaw ...
... May 12 NuRx Pharmaceuticals,Inc. (OTC Bulletin Board: NURX ... 9th, the Company,s 1-for-4 reverse stock split became,effective. The ... Bulletin,Board,s Corporate Actions group that, in connection with the ... to NUXP., The reverse stock split will reduce ...
... study supports the potential for QLT,s drug elution technology ... reduce and ... QLT Inc. (NASDAQ: QLTI; TSX:,QLT) announced today results from ... QLT Plug Delivery, Inc., of its punctal plug,drug delivery ...
Cached Biology Technology:BioMS Medical to present at Rodman and Renshaw Global Healthcare Conference 2NuRx Pharmaceuticals Announces Change of Ticker Symbol to NUXP, Reverse Stock Split Now in Effect 2QLT reports initial proof of concept data for punctal plug delivery technology 2QLT reports initial proof of concept data for punctal plug delivery technology 3QLT reports initial proof of concept data for punctal plug delivery technology 4
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/12/2015)... Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62/113114 for DISTRIBUTED METHOD AND SYSTEM ... The patent further establishes NXT-ID,s position in the emerging ... portfolio the ability for multiple devices to collaborate with ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... Mary had a little lamb, but only once a year. ... of a gene that prompts ewes to breed out of ... frequently. They conducted a simple genetic test to identify ... so-called M allele that other researchers had suspected might be ...
... ANN ARBOR, Mich.---A period of global warming from 53 million ... spurring a biodiversity boom in western North America, researchers from ... week in the Proceedings of the National Academy of ... a vast desert, and a few antelope and deer are ...
... Results of a new study confirm trends that different ... and worse cancer outcomes if they live in the United ... "Hispanics are not all the same with regard ... M.Sc., researcher in the Department of Epidemiology at the University ...
Cached Biology News:Mary had a lot of lambs: Researchers identify way to accelerate sheep breeding 2Climate-caused biodiversity booms and busts in ancient plants and mammals 2Moving to the US increases cancer risk for Hispanics 2Moving to the US increases cancer risk for Hispanics 3
...
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
Mouse monoclonal [ICRF 44] to Integrin alpha M...
... Focus Long has a long, ... from test tubes, bottles, flasks ... necked vessels. Finnpipette Focus Long ... select, it will be aspirated ...
Biology Products: